FDA approves Surfaxin

FDA approved Surfaxin lucinactant from Discovery Laboratories Inc. (NASDAQ:DSCO) to prevent respiratory distress syndrome in premature infants. The company first submitted an NDA to FDA for the product in 2004. Discovery Laboratories plans to launch the humanized lung surfactant in the U.S. late this year. ...